Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 18/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240219 | 0.90 | MAPK11 (0.65) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243751 | 0.89 | MAPK11 (0.70) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL240047 | 0.88 | MAPK11 (0.64) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL1752529 | 0.88 | MAPK11 (0.61) | HDAC1HDAC8HDAC6MAPK11MAPK14 | |
| SCHEMBL3317398 | 0.88 | NPC1 (0.67) | HDAC1HDAC8HDAC6MAPK11MAPK14 | |
| SCHEMBL3314095 | 0.87 | MAPK11 (0.57) | HDAC1HDAC8HDAC6MAPK11MAPK14 | |
| SCHEMBL10090837 | 0.86 | MAPK11 (0.58) | HDAC1HDAC8HDAC6MAPK11MAPK14 | |
| SCHEMBL242627 | 0.85 | CTDSP1 (0.58) | MAPK11MAPK14 | |
| SCHEMBL239606 | 0.85 | MAPK11 (0.67) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL239704 | 0.85 | MAPK14 (0.65) | MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | claimed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | disclosed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | HDAC1 84/4885HDAC8 393/4885HDAC6 51/4885 |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | HDAC1 90/4885HDAC8 442/4885HDAC6 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.